DND,,,,,most of yur post is bang on there big fella,,,it re-iterates what I have also posted in the past as well,,that RVX has not been capable of arriving at accurate trial costs nor time involved pre activity,,especially in regards to the BoM trial. It has challenged everyones nerves with these timing misses and cost over runs and probably our Management team as well.

Does DM deserve to be rich and happy??,,darn tooting,,he still is an incredible mind imo and no doubt means well to all. However, I think DM would serve better in the capacity of board chair only with a new and confirmed experienced CEO at the helm familiar to bringing drugs to market in that chair. A CEO change was discussed over the years, it just has never taken place. jmo